Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis appoints senior managers in emerging markets

This article was originally published in Scrip

Executive Summary

Sanofi-Aventis has appointed a number of senior managers in emerging markets. Patrick Aghanian who is currently head of the company's operations in Russia is becoming head of the Eurasia region. Apart from Russia, he will take responsibility for business in Ukraine, Belarus and central Asia (centred in Kazakhstan). He has previously worked in the region for a number of companies, including GlaxoSmithKline, Novartis and Sandoz. Thomas Kelly who is currently head of greater China has been promoted to head Asia Region covering also Thailand, Singapore, Malaysia, Indonesia, Vietnam and the Philippines. Mr Kelly's previous jobs included marketing positions in Johnson&Johnson, Novo Nordisk and Schering-Plough. Heraldo Marchezini, head of Sanofi-Aventis's business in Brazil, has been promoted to head of the Latin America region, and the responsibilities of Jeremy Moulding, head the Japan & Pacific Region, have been expanded to cover South Korea.

You may also be interested in...



Poland's new law fixes prices and trade mark-ups of reimbursed drugs

Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.

Global pharma boosts business in Russia - Why Russia (introduction)

In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.

Russia's president Medvedev wants talks on trials mutual recognition with US and EU

Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel